Abstract: A curable mixture and method of using the mixture are disclosed. In some embodiments, the mixture comprises a water soluble acrylate-based monomer, a water-soluble acrylamide-based monomer, or a mixture thereof, and has properties suitable for use as a tooth filling after curing.

Abstract: A curable mixture and method of using the mixture are disclosed. In some embodiments, the mixture comprises a water soluble acrylate-based monomer, a water-soluble acrylamide-based monomer, or a mixture thereof, and has properties suitable for use as a tooth filling after curing.

Abstract: A curable mixture and method of using the mixture are disclosed. In some embodiments, the mixture comprises an alginate polymer, and comprises properties suitable for use as a tooth filling after curing.

Abstract: A curable mixture and method of using the mixture are disclosed. In some embodiments, the mixture comprises a calcium silicate compound, a filler material, a non-aqueous carrier liquid, and a secondary carrier liquid, and has properties suitable for use as a tooth filling after curing.

Abstract: A curable mixture and method of using the mixture are disclosed. In some embodiments, the mixture comprises a water soluble acrylate-based monomer, a water-soluble acrylamide-based monomer, or a mixture thereof, and has properties suitable for use as a tooth filling after curing.

Abstract: The invention provides aliphatic epoxy-containing PEA polymer compositions with film-forming properties. The aliphatic epoxy di-acids used in the invention PEA compositions include non-toxic fatty aliphatic epoxy homologs. A second, C-protected L-lysine-based monomer can be introduced into the polymer to provide additional chain flexibility. The invention PEA polymer compositions are useful for delivery of bioactive agents when administered internally or used in the manufacture of implantable medical devices. Biodegradable hydrogels can be made using the invention epoxy-containing PEAs.

Abstract: The invention provides new aliphatic diester-di-acid-containing PEA polymer compositions with significant improvement in hydrolytic degradation rates as compared to aliphatic di-acid-containing PEA polymers. The di-acids used in the invention PEA compositions include non-toxic fatty aliphatic homologs. These molecules inherently contain two-ester groups, which easily can be cleaved by biotic (enzymatic) and abiotic hydrolysis. Additional di-acid-type compounds useful for active polycondensation are ?,?-alkylene dicarboxylates composed of short aliphatic non toxic diols and di-acids. In addition, the invention PEA polymer compositions optionally can include a second monomer, such as a C-protected L-lysine-based monomer, to introduce additional chain flexibility into the polymer. The invention PEA polymer compositions are useful for delivery of bioactive agents when administered internally.

Abstract: The invention provides biodegradable, water soluble PEA, PEUR and PEU carrier polymers, which can be used to conjugate, and thereby stabilize and/or solubilize, bioactive agents via polar uncharged or charged groups and activated ester or amino groups contained in the building blocks that make up the backbone of the polymer. The bioactive agents are released at a controlled rate determined by biodegradation of the polymers. The highly versatile Active Polycondensation (APC) method, which is mainly carried out in solution at mild temperatures, readily allows synthesis of such polymers. The invention water soluble polymers can also be used as water solubilizing tethers to attach drugs, and biologics to the surface of such carrier constructs as liposomes, particles and micelles.

Abstract: The present invention provides biodegradable polymer particle delivery compositions for delivery of macromolecular biologics, for example in crystal form, based on polymers, such as polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers, which contain amino acids in the polymer. The polymer particle delivery compositions can be formulated either as a liquid dispersion or a lyophilized powder of polymer particles containing bound water molecules with the macromolecular biologics, for example insulin, dispersed in the particles. Bioactive agents, such as drugs, polypeptides, and polynucleotides can also be delivered by using particles sized for local, oral, mucosal or circulatory delivery. Methods of delivering a macromolecular biologic with substantial native activity to a subject, for example orally, are also included.

Abstract: The invention provides high molecular weight, crystalline or semi crystalline biodegradable and biocompatible poly(ester urea) (PEU) polymers useful for making vascular stents and hard tissue replacement implants, such as bone substitutes. The PEU polymers are based on ? amino acids and are made by a polycondensation reaction. PEU polymer compositions can contain a therapeutic diol incorporated into the polymer backbone that is released from such an implant in situ. Bioactive agents, such as analgesics, antibiotics, and the like, can also be covalently attached to certain PEU polymers for release into tissue surrounding an implant during biodegradation of the polymer.

Abstract: The present invention provides biodegrable, biocompatible aromatic di-acid-containing poly(ester amide) (PEA) polymers with thermo-mechanical properties that can be readily tailored by selection of various combinations and proportions of the di-acid residues in the polymers. The polymers are suitable for use in production of drug-releasing biodegradable particles and implantable surgical devices, such as stents and internal fixation devices. The polymer compositions and surgical devices biodegrade in vivo by enzymatic action to release bioactive agents in a controlled manner over time as well as biocompatible breakdown products, including one to multiple different amino acids.

Abstract: The present invention provides biodegradable therapeutic polymer compositions based on poly(ester amide) (PEA), poly(ester urethane) (PEUR), and poly(ester urea) (PEU) polymers useful for in vivo delivery of at least one therapeutic diol or di-acid incorporated into the backbone of the biodegradable polymer. The therapeutic polymer compositions biodegrade in vivo by enzymatic action to release therapeutic diols or di-acids from the polymer backbone in a controlled manner over time. The invention compositions are stable, can be lyophilized for transportation and storage, and can be redispersed for administration. Due to structural properties of the PEA and PEUR polymers used, the invention therapeutic polymer compositions provide for high loading of the therapeutic diol or di-acid, as well as optional bioactive agents.

Abstract: The present invention provides synthetic vaccine delivery compositions based on polyester amide (PEA), polyester urethane (PEUR), and polyester urea (PEU) polymers for stimulating an immune response to a variety of pathogenic organisms and tumor cells in humans and other mammals. The vaccine delivery compositions are formulated as a liquid dispersion of polymer particles or molecules including class I or class II antigen peptides derived from organism or tumor cell proteins, which are taken up by antigen presenting cells of the mammal to induce an immune response in the mammal. Methods of inducing an immune response to the pathogenic organism or tumor cells in the invention compositions are also included.

Abstract: The present invention provides biodegradable polymer particle delivery compositions based on polymers, such as polyester amide (PEA) and polyester urethane (PEUR) polymers, that contain amino acids in the polymer. The polymer particle delivery compositions can be formulated as a liquid dispersion of polymer particles with the bioactive agents dispersed in the particle or conjugated attached to polymer molecules or particle surfaces. The bioactive agents can include drugs, polypeptides, DNA and cells for cell-based therapies using particles sized for local, mucosal or circulatory delivery. Methods of treating a disease by administering to a subject the polymer particle delivery composition, which incorporates a bioactive agent suitable for treatment of the disease, or its symptoms, are also included.